Blocking BAFF using a range of monoclonal antibodies reduces immunoglobulin G and auto-antibody titres (11, 12), which may explain its registered use in antibody-positive systemic lupus erythematosus (SLE) where it reduces organ damage and disease flares (11). This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.